JMA Task Force “Tell us about your project”
JMA Task Force “Tell us about your project”
Through this initiative, the EAACI Junior Members Assembly (JMA) aims to improve the communication skills of EAACI junior members, give visibility to their valuable contributions and share their innovative research. To this end, the JMs were asked to present their projects in three minutes with a single slide as visual support. The three best presentations receive a scholarship to the EAACI Congress, and they are disseminated through EAACI platforms.
The impact of normalized difference vegetation index (NDVI) and air pollution (NO2, NO, NOX) on inflammation indicators and human respiratory health using geographic information system and land use regression model – Pei-Chun Hsieh
Summary: This study believes that the increased concentrations of air pollutants NO2, NO, NOX will significantly reduce some lung function indicators, especially in women, such a trend can be clearly observed. By examining the specific pollutants and environmental factors that contribute to poor air quality, this study can help inform policymakers and public health officials about effective strategies to mitigate the negative effects of air pollution on human health.
Role of sex hormones in β2-receptor-mediated Relaxation in bronchial tissue – Ida Cerqua
Summary: With this work, we have demonstrated that there is a sex dimorphism in β2-receptor-mediated relaxation and this is attributed to the different expression of PDE4a and consequently a different level of cAMP between males and females. In addition, we found that estrogens play a key role in this sex dimorphism.
Uncovering New Tools for Severe Drug Allergy – Ana-Maria Copaescu
Summary: Delayed drug allergies are a group of adverse drug reactions that vary from isolated mild skin rashes to severe cutaneous adverse reactions (SCAR). In our project, we propose that the enzyme-linked immunoSpot, performed in specialized immunology laboratories, can be an alternative diagnostic tool when drug re-exposure via allergy skin testing is unavailable or associated with underlying risks.